Forum › News & Policy

Retatrutide and arrhythmia risks

9 replies6 peopleOct 10, 2026☆ Follow
Summary

Is retatrutide safe for people with a history of arrhythmia or atrial flutter?

Users with prior aflutter or AFib reported recurrences on retatrutide that resolved after stopping, while a cardiologist recommended switching to tirzepatide for its safety record and cardiac benefits. Others with SVT or PVC history experienced palpitations that improved with electrolyte supplementation, and some reached higher doses without problems. Retatrutide is noted to raise heart rate more than tirzepatide, and trial exclusions for arrhythmia history leave limited safety data.

What this discussion establishesWhere people disagree

Some users report no arrhythmia issues even at higher doses while others experienced repeated palpitations or recurrences that resolved only after stopping or adding electrolytes.

Still open

Whether retatrutide will ultimately carry arrhythmia warnings or prove cardioprotective like other GLP-1 agents once larger datasets exist.

Nothing here is advice.

9 replies · 6 people
SteadyCinder74archiveopening postOct 10

Anyone else willing to try retatrutide even with past arrhythmia? I figured on a small heart rate bump but learned later that anyone with arrhythmia history got left out of the middle and late trials over worries about flutter or AFib coming back. My wife and I both had treatment for a-flutter before. She had it return after roughly four months at a moderate final dose. We quit right away and got to the cardiologist fast. The doctor said the medication probably was not the cause but could not exclude it. He advised restarting a GLP-1 right away and favored the dual agonist because of more safety experience, evidence it lowers heart events like flutter, and because it already has full approval. She is back in normal rhythm and doing fine on that option. I have had no trouble myself and my long-standing extra beats actually seem less frequent.

PlainAlder11archiveOct 10

Sounds a lot like the AFIB episode I went through four years ago. I take two daily meds for it and have not had any return since. I increased to a high weekly dose on reta with no trouble at all.

SlowLantern29archiveOct 10
↳ replying to @SteadyCinder74 (opening post)

Good points! There is so much casual discussion here about reta that plenty of readers may not realize it still lacks full approval.

SharpCinder28archiveOct 10

A related long-running study is set to finish in 2029. Results from an earlier part of the program showed certain cardiovascular findings in the retatrutide groups.

SteadyCinder74archiveOct 10
↳ replying to @SharpCinder28

Those upcoming numbers should be useful. It is a shame the comparison arm uses placebo instead of the dual agonist that currently leads for these conditions.

SharpAlder17archiveOct 11

I had prior SVTs that were ablated before starting reta along with PVCs. Retatrutide, especially combined with alcohol, caused noticeable palpitations. They faded after pausing and resuming slowly, but returned with later dose increases when I split doses twice weekly. After several cycles I began daily electrolyte packets containing potassium and magnesium. The magnesium tablets alone did nothing. I tried various mixes and stayed with one brand that was inexpensive and had a broad profile without much sodium. Taking it every day fixed the issue and actually left me feeling better than before. Stopping the packets brought the irregular beats back quickly, and restarting cleared them again. Alcohol still worsens it but I am keeping all three habits. Flutter and AFib are more serious so I am unsure I would have continued the same way.

CopperSignal27archiveOct 11

With any past atrial fibrillation or other rhythm disturbance, the dual agonist looks like the safer option unless there is a strong reason to choose reta instead. Retatrutide lifts resting heart rate more than the dual agonist. At least three others here have described AF episodes starting soon after beginning reta, while none have mentioned the same with the dual agonist. No published case reports exist yet, which fits the pattern that far more people are using the grey version than were ever in trials, so rarer effects surface first outside studies. This situation is unusual because a drug still in testing is already in wide unofficial use. Retatrutide will probably show heart protection similar to other GLP-1 drugs, yet it may still receive a caution for arrhythmia patients especially at the start.

PlainAlder11archiveOct 11
↳ replying to @SlowLantern29

I agree that many probably do not realize the approval status. My AFIB four years ago was triggered by a severe double pneumonia that landed me in intensive care for two weeks. I have stayed free of it since, and my most recent heart scan looked excellent according to the cardiologist.

SharpCinder28archiveOct 11
↳ replying to @SlowLantern29

When the agency reviews the data it will likely either bar use outright in anyone with prior atrial fibrillation or serious fast rhythms because those patients were deliberately kept out of the main studies for safety reasons, or it will require regular ECG checks and heart-rate logs for milder past cases while steering doctors toward other GLP-1 options first. That is the same caution I apply to growth hormone, which carries approval yet is among the worst peptides for triggering afib because of fluid retention.

SharpCinder28archiveOct 11
↳ replying to @SharpAlder17

For anyone starting reta who already has some history of afib, an SGLT2 inhibitor plus taurine and similar supplements might offer added support.

Related discussions

Add your experience

If you have tried it, this topic is still open. Sign in to reply — it takes a minute.